0001104659-24-006379.txt : 20240125
0001104659-24-006379.hdr.sgml : 20240125
20240125060013
ACCESSION NUMBER: 0001104659-24-006379
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240125
DATE AS OF CHANGE: 20240125
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burns John Thomas
CENTRAL INDEX KEY: 0001568734
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33958
FILM NUMBER: 24558446
MAIL ADDRESS:
STREET 1: 16760 SW UPPER BOONES FERRY RD
STREET 2: SUITE 101
CITY: PORTLAND
STATE: X1
ZIP: 97224
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc.
CENTRAL INDEX KEY: 0001390478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 6462005278
MAIL ADDRESS:
STREET 1: 7 TIMES SQUARE
STREET 2: SUITE 2503
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Galena Biopharma, Inc.
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: RXi Pharmaceuticals Corp
DATE OF NAME CHANGE: 20110926
FORMER COMPANY:
FORMER CONFORMED NAME: GALENA BIOPHARMA, INC.
DATE OF NAME CHANGE: 20110922
4
1
tm243935-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-22
0
0001390478
SELLAS Life Sciences Group, Inc.
SLS
0001568734
Burns John Thomas
C/O SELLAS LIFE SCIENCES GROUP, INC.,
7 TIMES SQUARE, SUITE 2503
NEW YORK
NY
10036
0
1
0
0
CFO
0
Common Stock
2024-01-22
4
A
0
47000
0.00
A
101927
D
Stock Option (Right to Buy)
0.5195
2024-01-22
4
A
0
75000
0
A
2034-01-22
Common Stock
75000
75000
D
The Reporting Person received an award of 47,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
/s/ John Burns
2024-01-24